Long-term outcomes and dynamic changes of in-stent stenosis after Pipeline embolization device treatment of intracranial aneurysms

医学 狭窄 栓塞 动脉瘤 闭塞 血管成形术 支架 分流器 气球 外科 逻辑回归 放射科 内科学
作者
Siming Gui,Xiheng Chen,Dachao Wei,Dingwei Deng,Wei You,Xiangyu Meng,Jian Lv,Junqiang Feng,Yudi Tang,Shu Yang,Ting Chen,Peng Liu,Huijian Ge,Hengwei Jin,Xinke Liu,Yuhua Jiang,Wei Feng,Youxiang LI
出处
期刊:Journal of NeuroInterventional Surgery [BMJ]
卷期号:15 (12): 1187-1193 被引量:18
标识
DOI:10.1136/jnis-2022-019680
摘要

Background Flow diverters have revolutionized the treatment of intracranial aneurysms. However, the delayed complications associated with flow diverter use are unknown. Objective To evaluate the incidence, severity, clinical outcomes, risk factors, and dynamic changes associated with in-stent stenosis (ISS) after treatment with a Pipeline embolization device (PED). Methods Patients who underwent PED treatment between 2015 and 2020 were enrolled. The angiographic, clinical, and follow-up data of 459 patients were independently reviewed by four neuroradiologists to identify ISS. Binary logistic regression was conducted to determine ISS risk factors, and an ISS–time curve was established to demonstrate dynamic changes in ISS after PED implantation. Results Of the 459 treated patients, 69 (15.0%) developed ISS. At follow-up, nine patients (2.0%) with ISS demonstrated reversal, while 18 (3.9%) developed parental artery occlusion. A total of 380 patients (82.8%) achieved complete aneurysm occlusion (O’Kelly–Marotta grade D). Patients with posterior-circulation aneurysm (OR=2.895, 95% CI (1.732 to 4.838; P<0.001) or balloon angioplasty (OR=1.992, 95% CI 1.162 to 3.414; P=0.037) were more likely to develop ISS. Patients aged >54 years (OR=0.464, 95% CI 0.274 to 0.785; P=0.006) or with a body mass index of >28 kg/m 2 (OR=0.427, 95% CI 0.184 to 0.991; P=0.026) had a lower ISS risk. Intimal hyperplasia initiated by PED placement peaked within 1 year after the procedure, rarely progressed after 12 months, and tended to reverse within 24 months. Conclusions ISS is a common, benign, and self-limiting complication of PED implantation in the Chinese population.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小桶爸爸完成签到,获得积分10
刚刚
刚刚
zhangsudi完成签到,获得积分10
刚刚
herococa应助阿言采纳,获得10
1秒前
2秒前
CART汪完成签到,获得积分10
3秒前
櫹櫆完成签到 ,获得积分10
4秒前
ZHANGXUEJUN发布了新的文献求助100
4秒前
哈哈2022完成签到,获得积分10
5秒前
个性梦蕊发布了新的文献求助10
5秒前
ChatGPT发布了新的文献求助10
6秒前
李安全完成签到,获得积分10
7秒前
Dan完成签到,获得积分10
7秒前
尽平梅愿完成签到,获得积分10
7秒前
泪雨煊完成签到,获得积分10
8秒前
ding应助永远的阿科采纳,获得20
8秒前
聚散流沙完成签到,获得积分10
9秒前
夜曦完成签到 ,获得积分10
9秒前
AZN完成签到,获得积分10
12秒前
hc完成签到 ,获得积分10
12秒前
充电宝应助个性梦蕊采纳,获得10
13秒前
wxZeng完成签到,获得积分10
13秒前
yt完成签到,获得积分10
14秒前
微笑书白发布了新的文献求助10
14秒前
夏沫完成签到,获得积分10
15秒前
活力鸡完成签到,获得积分10
16秒前
鸭子完成签到,获得积分10
16秒前
WX发布了新的文献求助10
16秒前
18秒前
Bruce Lin完成签到,获得积分10
18秒前
江十三完成签到,获得积分10
19秒前
yang完成签到,获得积分10
19秒前
张一完成签到,获得积分10
19秒前
lbx完成签到,获得积分10
20秒前
zycorner完成签到,获得积分10
21秒前
初心完成签到 ,获得积分10
22秒前
搜集达人应助呱呱采纳,获得10
22秒前
Katyusha完成签到 ,获得积分10
23秒前
现实芒果完成签到,获得积分10
24秒前
冷冷暴力完成签到,获得积分10
26秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
Residual Stress Measurement by X-Ray Diffraction, 2003 Edition HS-784/2003 588
T/CIET 1202-2025 可吸收再生氧化纤维素止血材料 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3950021
求助须知:如何正确求助?哪些是违规求助? 3495348
关于积分的说明 11076451
捐赠科研通 3225877
什么是DOI,文献DOI怎么找? 1783346
邀请新用户注册赠送积分活动 867596
科研通“疑难数据库(出版商)”最低求助积分说明 800839